Clinigen inks partnership agreement with Eyevance Pharmaceuticals

Pharmaceutical firm Clinigen said on Thursday that it has inked an exclusive partnership agreement with Eyevance Pharmaceuticals, a wholly-owned subsidiary of Santen Pharmaceutical.

Clinigen stated it will team up with Eyevance to manage the supply and distribution of NATACYN 5%, an ocular antifungal drug for topical administration, in Argentina, Colombia, Botswana, Mauritius, South Africa, Hong Kong, Thailand, Malaysia, Singapore and Taiwan.

Under the terms of the agreement, the AIM-listed group will manage all elements of the program including healthcare practitioner enquiry management, regulatory oversight, logistics and access management.

Chief operating officer Sam Herbert said: "This agreement demonstrates the value of our lifecycle platform and our commitment in partnering with pharmaceutical companies to provide physicians and pharmacists around the world with access to important medicines that improve the quality of patients' lives."

Separately, Clinigen said its Erwinase 10,000 IU/vial, was now available for unrestricted supply in the United Kingdom, with previous restrictions on allocation, introduced due to supply constraints on 6 April, now being removed.

As of 1045 BST, Clinigen shares were down 0.73% at 610.50p.